. Parmi-les-patients-en-Échec-virologique, 10) ont déclaré un défaut d'observance. -100% (10/10) avaient un antécédent de traitement par INI de première génération, contre 70% (26/37) des patients en succès, avec dans 100% des cas un antécédent d'échec sous ce traitement, p.49

. Sur-le-plan-métabolique, 9%) étaient dyslipidémiques Parmi eux, 12 étaient sous traitement hypolipémiant Sur ces 12 patients, aucun n'a nécessité de majoration du traitement hypolipémiant après mise sous DTG. En revanche, 4 ont pu bénéficier de l'arrêt ou de l'allègement de ce traitement. Dans 1 cas il s'agissait d'un patient chez qui un traitement par ETV avait été arrêté Dans un cas, seule l'IP avait été modifiée (passage de DRV/r+EPV à TPV/r+ EPV+ DTG+ T20) Dans un cas, un traitement par Trizivir avait été remplacé par ABC, 3TC+DTG. Enfin, pp.22-48

. Aucun-n-'était-passé-d, une stratégie avec IP à une stratégie sans IP. Dans 1 cas le patient n'avait pas d'IP initialement, dans 1 cas l'IP a été maintenu dans le traitement avec le DTG, dans deux cas l'IP a été modifiée

R. Nájera, M. Herrera, and R. De-andrés, Human immunodeficiency virus and related retroviruses, West J Med. déc, vol.147, issue.6, pp.702-710, 1987.

D. Gelderblom, M. Özel, and G. Pauli, Morphogenesis and morphology of HIV structure-function relations, Archives of Virology, vol.332, issue.1-2, pp.1-13, 1989.
DOI : 10.1007/BF01311033

A. Seelamgari, A. Maddukuri, R. Berro, C. La-fuente, . De et al., Role of viral regulatory and accessory proteins in HIV-1 replication, Frontiers in Bioscience, vol.9, issue.1-3, pp.2388-413, 2004.
DOI : 10.2741/1403

A. Pasquet and Y. Yazdanpanah, infection à VIH, Rev Prat. Fevrier, vol.62, issue.2, pp.255-63, 2012.

B. Roquebert, F. Damond, F. Brun-vézinet, and D. Descamps, Diversit?? g??n??tique des VIH et ses cons??quences, Pathologie Biologie, vol.57, issue.2, pp.142-150, 2009.
DOI : 10.1016/j.patbio.2008.04.004

J. Plantier, M. Leoz, J. Dickerson, D. Oliveira, F. Cordonnier et al., A new human immunodeficiency virus derived from gorillas, Nature Medicine, vol.24, issue.8, pp.871-873, 2009.
DOI : 10.1038/nm.2016

G. Pantaleo, C. Graziosi, and A. Fauci, New concepts in the immunopathogenesis of human immunodeficiency virus infection, N Engl J Med. 4 févr, vol.328, issue.5, pp.327-362, 1993.

A. Haase, Targeting early infection to prevent HIV-1 mucosal transmission, Nature, vol.183, issue.7286, pp.217-240, 2010.
DOI : 10.1038/nature08757

G. Pantaleo, C. Graziosi, J. Demarest, L. Butini, M. Montroni et al., HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease, Nature, vol.362, issue.6418, pp.355-363, 1993.
DOI : 10.1038/362355a0

D. Cohen and B. Walker, Human Immunodeficieny Virus Pathogenesis and Prospects for Immune Control in Patients with Established Infection, Clinical Infectious Diseases, vol.32, issue.12, pp.1756-68, 2001.
DOI : 10.1086/320759

L. Picker, Immunopathogenesis of acute AIDS virus infection, Current Opinion in Immunology, vol.18, issue.4, pp.399-405, 2006.
DOI : 10.1016/j.coi.2006.05.001

B. Autran, F. Hadida, and G. Haas, Evolution and plasticity of CTL responses against HIV, Current Opinion in Immunology, vol.8, issue.4, pp.546-53, 1996.
DOI : 10.1016/S0952-7915(96)80045-8

V. Appay and D. Sauce, Immune activation and inflammation in HIV-1 infection: causes and consequences, The Journal of Pathology, vol.125, issue.2, pp.231-272, 2008.
DOI : 10.1002/path.2276

J. Siliciano and R. Siliciano, A long-term latent reservoir for HIV-1: discovery and clinical implications, Journal of Antimicrobial Chemotherapy, vol.54, issue.1, pp.6-9, 2004.
DOI : 10.1093/jac/dkh292

M. Cadogan and A. Dalgleish, HIV immunopathogenesis and strategies for intervention, The Lancet Infectious Diseases, vol.8, issue.11, pp.675-84, 2008.
DOI : 10.1016/S1473-3099(08)70205-6

J. Levy, Infection by Human Immunodeficiency Virus ??? CD4 is Not Enough, New England Journal of Medicine, vol.335, issue.20, pp.1528-1558, 1996.
DOI : 10.1056/NEJM199611143352011

M. Gandhi and R. Gandhi, Single-pill combination regimens for treatment of HIV-1 infection, N Engl J Med. 17 juill, vol.371, issue.3, pp.248-59, 2014.

M. Furtado, D. Callaway, J. Phair, K. Kunstman, J. Stanton et al., Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy, New England Journal of Medicine, vol.340, issue.21, pp.1614-1636, 1999.
DOI : 10.1056/NEJM199905273402102

E. Berger, R. Doms, E. Fenyö, B. Korber, D. Littman et al., A new classification for HIV-1, Nature, vol.391, issue.6664, p.240, 1998.
DOI : 10.1038/34571

M. Chowers, B. Gottesman, L. Leibovici, J. Schapiro, and M. Paul, Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis, European Journal of Clinical Microbiology & Infectious Diseases, vol.22, issue.14, pp.779-86, 2010.
DOI : 10.1007/s10096-010-0926-y

J. Ma, K. Lee, and G. Kuo, HLA-B*5701 testing to predict abacavir hypersensitivity, PLoS Currents, vol.2, p.1203, 2010.
DOI : 10.1371/currents.RRN1203

P. Morlat, Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'expert, 2013.

P. Morlat, Prise en charge médicales des patients vivant avec le VIH. Actualisation, 2013.

N. Sluis-cremer and G. Tachedjian, Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors, Virus Research, vol.134, issue.1-2, pp.147-56, 2008.
DOI : 10.1016/j.virusres.2008.01.002

P. Frange, L. Assoumou, D. Descamps, A. Chéret, C. Goujard et al., HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies, J Antimicrob Chemother. juill, vol.70, issue.7, pp.2084-2093, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01486966

I. Usach, V. Melis, and J. Peris, Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability, Journal of the International AIDS Society, vol.16, issue.1, pp.1-14, 2013.
DOI : 10.7448/IAS.16.1.18567

Y. Pommier, A. Johnson, and C. Marchand, Integrase inhibitors to treat HIV/Aids, Nature Reviews Drug Discovery, vol.17, issue.3, pp.236-284, 2005.
DOI : 10.1038/nrd1660

M. Metifiot, C. Marchand, K. Maddali, and Y. Pommier, Resistance to Integrase Inhibitors, Viruses, vol.2, issue.7, pp.1347-66, 2010.
DOI : 10.3390/v2071347

J. Mouscadet, Structures et rôles de l'intégrase dans le cycle viral, Virologie, vol.11, issue.35, pp.143-52, 2007.

J. Mouscadet and L. Tchertanov, Raltegravir: molecular basis of its mechanism of action, European Journal of Medical Research, vol.14, issue.Suppl 3, pp.5-16, 2009.
DOI : 10.1021/jm025553u

O. Delelis, K. Carayon, A. Saïb, E. Deprez, and J. Mouscadet, Integrase and integration: biochemical activities of HIV-1 integrase, Retrovirology, vol.5, issue.1, p.114, 2008.
DOI : 10.1186/1742-4690-5-114

J. Croxtall, K. Lyseng-williamson, and C. Perry, Raltegravir, Drugs, vol.43, issue.5, pp.131-139, 2008.
DOI : 10.2165/00003495-200868010-00009

T. Mesplede and M. Wainberg, Integrase Strand Transfer Inhibitors in HIV Therapy, Infectious Diseases and Therapy, vol.10, issue.1, pp.83-93, 2013.
DOI : 10.1007/s40121-013-0020-8

D. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock et al., Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells, Science, vol.287, issue.5453, pp.646-50, 2000.
DOI : 10.1126/science.287.5453.646

C. Marchand, X. Zhang, G. Pais, K. Cowansage, N. Neamati et al., Structural Determinants for HIV-1 Integrase Inhibition by ??-Diketo Acids, Journal of Biological Chemistry, vol.277, issue.15, pp.12596-603, 2002.
DOI : 10.1074/jbc.M110758200

J. Rockstroh, E. Dejesus, J. Lennox, Y. Yazdanpanah, M. Saag et al., Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1???Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.1, pp.77-85, 1999.
DOI : 10.1097/QAI.0b013e31828ace69

J. Lennox, R. Landovitz, H. Ribaudo, I. Ofotokun, L. Na et al., Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor???Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1, Annals of Internal Medicine, vol.161, issue.7, pp.461-71, 2014.
DOI : 10.7326/M14-1084

F. Raffi, A. Babiker, L. Richert, J. Molina, E. George et al., Ritonavirboosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet. 4 août, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01108186

J. Eron, D. Cooper, R. Steigbigel, B. Clotet, J. Gatell et al., Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials, The Lancet Infectious Diseases, vol.13, issue.7, pp.587-96, 2013.
DOI : 10.1016/S1473-3099(13)70093-8

S. Group, M. Boyd, N. Kumarasamy, C. Moore, C. Nwizu et al., Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study, Lancet. 15 juin, vol.381, issue.9883, pp.2091-2100, 2013.

J. Eron, Y. B. Cooper, D. Youle, M. Dejesus, E. Andrade-villanueva et al., Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials, The Lancet, vol.375, issue.9712, pp.396-407, 2010.
DOI : 10.1016/S0140-6736(09)62041-9

E. Martínez, M. Larrousse, J. Llibre, F. Gutiérrez, M. Saumoy et al., Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study, AIDS, vol.24, issue.11, pp.1697-707, 2010.
DOI : 10.1097/QAD.0b013e32833a608a

M. Fabbiani, A. Mondi, M. Colafigli, G. Ettorre, F. Paoletti et al., Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study), Scandinavian Journal of Infectious Diseases, vol.26, issue.1, pp.34-45, 2014.
DOI : 10.1016/S0140-6736(02)08706-8

S. Gallien, J. Braun, C. Delaugerre, I. Charreau, J. Reynes et al., Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial, Journal of Antimicrobial Chemotherapy, vol.66, issue.9, pp.2099-106, 2011.
DOI : 10.1093/jac/dkr269

I. Ofotokun, A. Sheth, S. Sanford, K. Easley, N. Shenvi et al., A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study, AIDS Research and Human Retroviruses, vol.28, issue.10, pp.1196-206, 2012.
DOI : 10.1089/aid.2011.0336

T. Nishijima, H. Gatanaga, T. Shimbo, H. Komatsu, T. Endo et al., Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial, PLoS ONE, vol.28, issue.8, p.73639, 2013.
DOI : 10.1371/journal.pone.0073639.s002

J. Eron, J. Rockstroh, J. Reynes, J. Andrade-villanueva, J. Ramalho-madruga et al., Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial, The Lancet Infectious Diseases, vol.11, issue.12, pp.907-922, 2011.
DOI : 10.1016/S1473-3099(11)70196-7

C. Delaugerre, Barri??re g??n??tique ?? la r??sistance des antir??troviraux, M??decine et Maladies Infectieuses, vol.40, issue.1, pp.1-10, 2010.
DOI : 10.1016/S0399-077X(10)70001-9

D. Cooper, R. Steigbigel, J. Gatell, J. Rockstroh, C. Katlama et al., Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, New England Journal of Medicine, vol.359, issue.4, pp.355-65, 2008.
DOI : 10.1056/NEJMoa0708978

D. Da-silva, L. Van-wesenbeeck, D. Breilh, S. Reigadas, G. Anies et al., HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens, Journal of Antimicrobial Chemotherapy, vol.65, issue.6, pp.1262-1271, 2010.
DOI : 10.1093/jac/dkq099

URL : https://hal.archives-ouvertes.fr/hal-00594696

J. Grobler and D. Hazuda, Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences, Current Opinion in Virology, vol.8, pp.98-103, 2014.
DOI : 10.1016/j.coviro.2014.07.006

S. Reigadas, B. Masquelier, C. Calmels, M. Laguerre, E. Lazaro et al., Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3187-94, 2011.
DOI : 10.1128/AAC.00071-11

I. Malet, O. Delelis, M. Valantin, B. Montes, C. Soulie et al., Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1351-1359, 2008.
DOI : 10.1128/AAC.01228-07

H. Autorité and D. Santé, Test génotypique de résistance aux inhibiteurs de l'intégrase ? Rapport d'évaluation, 2010.

S. Reigadas, G. Anies, B. Masquelier, C. Calmels, L. Stuyver et al., The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions, PLoS ONE, vol.5, issue.4, p.10311, 2010.
DOI : 10.1371/journal.pone.0010311.s001

URL : https://hal.archives-ouvertes.fr/hal-00522695

M. Sato, T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita et al., Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics, Journal of Medicinal Chemistry, vol.49, issue.5, pp.1506-1514, 2006.
DOI : 10.1021/jm0600139

A. Zolopa, P. Sax, E. Dejesus, A. Mills, C. Cohen et al., A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.1, pp.96-100, 1999.
DOI : 10.1097/QAI.0b013e318289545c

E. Dejesus, J. Rockstroh, K. Henry, J. Molina, J. Gathe et al., Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet, pp.2429-2467, 2012.

R. Elion, J. Molina, R. A. López, J. Cooper, D. Maggiolo et al., A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.63, issue.4, pp.494-501, 1999.
DOI : 10.1097/QAI.0b013e318298469c

J. Arribas, G. Pialoux, J. Gathe, D. Perri, G. Reynes et al., Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial, The Lancet Infectious Diseases, vol.14, issue.7, pp.581-590, 2014.
DOI : 10.1016/S1473-3099(14)70782-0

A. Pozniak, M. Markowitz, A. Mills, H. Stellbrink, A. Antela et al., Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial, The Lancet Infectious Diseases, vol.14, issue.7, pp.590-599, 2014.
DOI : 10.1016/S1473-3099(14)70796-0

A. Mills, G. Crofoot, R. Ortiz, B. Rashbaum, W. Towner et al., Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1???Infected Subjects: 48 Weeks Data, HIV Clinical Trials, vol.17, issue.5, pp.51-57, 2014.
DOI : 10.1016/S0140-6736(12)60917-9

P. German, H. Liu, J. Szwarcberg, M. Hepner, J. Andrews et al., Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.61, issue.1, pp.32-40, 1999.
DOI : 10.1097/QAI.0b013e3182645648

J. Lee, A. Calmy, I. Andrieux-meyer, and N. Ford, Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings, HIVAIDS Auckl NZ, vol.4, pp.5-15, 2012.

J. Adams, B. Greener, and A. Kashuba, Pharmacology of HIV integrase inhibitors, Current Opinion in HIV and AIDS, vol.7, issue.5, pp.390-400, 2012.
DOI : 10.1097/COH.0b013e328356e91c

M. Youle, Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients, Journal of Antimicrobial Chemotherapy, vol.60, issue.6, pp.1195-205, 2007.
DOI : 10.1093/jac/dkm364

M. Foisy, E. Yakiwchuk, and C. Hughes, Induction Effects of Ritonavir: Implications for Drug Interactions, Annals of Pharmacotherapy, vol.19, issue.3, pp.1048-59, 2008.
DOI : 10.1097/FTD.Ob013e318030defO

B. Nathan, J. Bayley, L. Waters, and F. Post, Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors, Infectious Diseases and Therapy, vol.22, issue.1, pp.111-133, 2013.
DOI : 10.1007/s40121-013-0013-7

B. Shah, J. Schafer, J. Priano, and K. Squires, Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.379, issue.10, pp.1107-1123, 2013.
DOI : 10.1002/phar.1237

P. German, D. Warren, S. West, J. Hui, and B. Kearney, Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.55, issue.3, pp.323-332, 1999.
DOI : 10.1097/QAI.0b013e3181eb376b

E. Deeks, Elvitegravir: A Review of Its Use in Adults with HIV-1 Infection, Drugs, vol.36, issue.3, pp.687-97, 2014.
DOI : 10.1007/s40265-014-0206-8

O. Goethals, R. Clayton, M. Van-ginderen, I. Vereycken, E. Wagemans et al., Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors, Journal of Virology, vol.82, issue.21, pp.10366-74, 2008.
DOI : 10.1128/JVI.00470-08

C. Garrido, J. Villacian, N. Zahonero, T. Pattery, F. Garcia et al., Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.2873-2881, 2012.
DOI : 10.1128/AAC.06170-11

R. Kulkarni, M. Abram, D. Mccoll, T. Barnes, M. Fordyce et al., Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Na??ve Patients, HIV Clinical Trials, vol.19, issue.4, pp.218-248, 2014.
DOI : 10.1093/infdis/jis750

K. White, R. Kulkarni, D. Mccoll, M. Rhee, J. Szwarcberg et al., Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients, Antiviral Therapy, vol.20, issue.3, 2014.
DOI : 10.3851/IMP2885

M. Cottrell, T. Hadzic, and A. Kashuba, Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir, Clinical Pharmacokinetics, vol.37, issue.9, pp.981-94, 2013.
DOI : 10.1007/s40262-013-0093-2

S. Hare, S. Smith, M. Métifiot, A. Jaxa-chamiec, Y. Pommier et al., Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572), Molecular Pharmacology, vol.80, issue.4, pp.565-72, 2011.
DOI : 10.1124/mol.111.073189

K. Hightower, R. Wang, F. Deanda, B. Johns, K. Weaver et al., Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes, Antimicrobial Agents and Chemotherapy, vol.55, issue.10, pp.4552-4561, 2011.
DOI : 10.1128/AAC.00157-11

F. Deanda, K. Hightower, R. Nolte, K. Hattori, T. Yoshinaga et al., Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics, PLoS ONE, vol.49, issue.10, p.77448, 2013.
DOI : 10.1371/journal.pone.0077448.s002

J. Van-lunzen, F. Maggiolo, J. Arribas, A. Rakhmanova, P. Yeni et al., Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial, The Lancet Infectious Diseases, vol.12, issue.2, pp.111-119, 2012.
DOI : 10.1016/S1473-3099(11)70290-0

F. Raffi, H. Jaeger, E. Quiros-roldan, H. Albrecht, E. Belonosova et al., Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial, The Lancet Infectious Diseases, vol.13, issue.11, pp.927-962, 2013.
DOI : 10.1016/S1473-3099(13)70257-3

B. Clotet, J. Feinberg, J. Van-lunzen, K. Antinori, A. Dumitru et al., Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, The Lancet, vol.383, issue.9936, pp.2222-2253, 2014.
DOI : 10.1016/S0140-6736(14)60084-2

S. Walmsley, A. Antela, N. Clumeck, D. Duiculescu, A. Eberhard et al., Dolutegravir plus Abacavir???Lamivudine for the Treatment of HIV-1 Infection, New England Journal of Medicine, vol.369, issue.19, pp.1807-1825, 2013.
DOI : 10.1056/NEJMoa1215541

P. Cahn, A. Pozniak, H. Mingrone, A. Shuldyakov, C. Brites et al., Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study, The Lancet, vol.382, issue.9893, pp.700-708, 2013.
DOI : 10.1016/S0140-6736(13)61221-0

J. Eron, B. Clotet, J. Durant, C. Katlama, P. Kumar et al., Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study, Journal of Infectious Diseases, vol.207, issue.5, pp.740-748, 2013.
DOI : 10.1093/infdis/jis750

A. Castagna, F. Maggiolo, G. Penco, D. Wright, A. Mills et al., Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study, Journal of Infectious Diseases, vol.210, issue.3, pp.354-62, 2014.
DOI : 10.1093/infdis/jiu051

B. Akil, G. Blick, D. Hagins, M. Ramgopal, G. Richmond et al., Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study, Antivir Ther. 16 oct, 2014.

I. Song, J. Borland, S. Chen, P. Patel, T. Wajima et al., Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir, Antimicrobial Agents and Chemotherapy, vol.56, issue.3, pp.1627-1636, 2012.
DOI : 10.1128/AAC.05739-11

S. Min, I. Song, J. Borland, S. Chen, Y. Lou et al., Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers, Antimicrobial Agents and Chemotherapy, vol.54, issue.1, pp.254-262, 2010.
DOI : 10.1128/AAC.00842-09

S. Weller, J. Borland, S. Chen, M. Johnson, P. Savina et al., Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment, European Journal of Clinical Pharmacology, vol.51, issue.2, pp.29-35, 2014.
DOI : 10.1007/s00228-013-1590-9

K. Dooley, P. Sayre, J. Borland, E. Purdy, S. Chen et al., Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.62, issue.1, pp.21-28, 1999.
DOI : 10.1097/QAI.0b013e318276cda9

E. Lepist, X. Zhang, J. Hao, J. Huang, A. Kosaka et al., Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat, Kidney International, vol.86, issue.2, pp.350-357, 2014.
DOI : 10.1038/ki.2014.66

P. Mccormack, Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults, Drugs, vol.21, issue.1, pp.1241-52, 2014.
DOI : 10.1007/s40265-014-0256-y

J. Koteff, J. Borland, S. Chen, I. Song, A. Peppercorn et al., A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects, British Journal of Clinical Pharmacology, vol.39, issue.2 Suppl. 1, pp.990-996, 2013.
DOI : 10.1111/j.1365-2125.2012.04440.x

M. Kobayashi, T. Yoshinaga, T. Seki, C. Wakasa-morimoto, K. Brown et al., In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, Antimicrobial Agents and Chemotherapy, vol.55, issue.2, pp.813-834, 2011.
DOI : 10.1128/AAC.01209-10

M. Wainberg, K. Anstett, T. Mesplede, P. Quashie, Y. Han et al., The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound, Journal of the International AIDS Society, vol.17, issue.4(Suppl 3), 2014.
DOI : 10.7448/IAS.17.4.19518

T. Mesplède and M. Wainberg, Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses, pp.3377-85, 2014.

P. Quashie, T. Mesplède, Y. Han, M. Oliveira, D. Singhroy et al., Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir, Journal of Virology, vol.86, issue.5, pp.2696-705, 2012.
DOI : 10.1128/JVI.06591-11

F. Canducci, E. Ceresola, E. Boeri, V. Spagnuolo, F. Cossarini et al., Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir, Journal of Infectious Diseases, vol.204, issue.11, pp.1811-1816, 2011.
DOI : 10.1093/infdis/jir636

M. Underwood, B. Johns, A. Sato, J. Martin, S. Deeks et al., The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.61, issue.3, pp.297-301, 1999.
DOI : 10.1097/QAI.0b013e31826bfd02

A. Frantzell, Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1

M. Underwood, Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor- Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)